PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Visiongain

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Global Nuclear Medicine Market will Reach $4.5Bn by 2022 Visiongain Report Predicts - A new report by visiongain, a London-based business information provider, predicts that the global market for nuclear medicine will be worth $4.5bn by 2022. The market generated sales of $1.4bn in 2010 - Visiongain.com
Global Nuclear Medicine Market will Reach $4.5Bn by 2022 Visiongain Report Predicts

 

NewswireToday - /newswire/ - London, United Kingdom, 2012/05/04 - A new report by visiongain, a London-based business information provider, predicts that the global market for nuclear medicine will be worth $4.5bn by 2022. The market generated sales of $1.4bn in 2010 - Visiongain.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The medical device industry has witnessed explosive growth in recent years. According to visiongain estimates, the global market was worth $236.1bn in 2010. Much of this growth is linked to the rising prevalence of a number of diseases worldwide; most notably in cardiac and neurological systems. This has fuelled a strong demand for technically advanced medical and diagnostic imaging devices, capable of providing accurate and detailed diagnoses, which can allow earlier, and potentially life-saving, medical intervention.

Hemant Mistry, healthcare industry analyst, says: “Despite experiencing a decline in sales volume and reduced demand in the aftermath of the global economic recession, the nuclear medicine market recovered well, and has seen strong growth in recent years. Much of this growth has been linked to the advent of hybrid units, such as positron emission tomography/computed tomography (PET/CT) scans, where both anatomical and functional images can be captured. For example, the combination of Positron Emission Tomography (PET) with other imaging modalities, such as MRI (Magnetic Resonance Imaging) has allowed for the imaging of cartilage damage, previously thought unreliable.”

Visiongain’s research also suggests that the world nuclear medicine market may benefit from globalisation. Developed nuclear medicine markets such as the US and UK are highly saturated and the focus is likely to be towards upgrading stand-alone PET and SPECT system with fully integrated hybrid units, that offer a high level of anatomical and functional detail. Emerging countries such as China and India will offer more opportunity, due a lack of nuclear medicine facilities and technologies, and increased healthcare spending. It has been predicted that healthcare investment in these countries is expected to double in the next seven years.

Visiongain predicts that this market will grow rapidly to 2022. The future of the nuclear medicine market appears promising as technological innovations such as PET and SPECT systems allow highly accurate diagnostic images to be produced, allowing for earlier, and potentially life saving medical intervention to be initiated. The drive to provide patients with diagnostic imaging systems options that are more accurate, comfortable and future-proof will sustain growth in the nuclear medicine market during the forecast period. This new report adds to visiongain’s wide range of analytical reports in healthcare and other industry areas.

For sample pages and further information concerning the visiongain report Nuclear Medicine Imaging Devices: Global Market Prospects 2012-2022 please visit the website.

About visiongain
Visiongain (visiongain.com) is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Aviation and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Visiongain

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Global Nuclear Medicine Market will Reach $4.5Bn by 2022 Visiongain Report Predicts

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sara Peerun - Visiongain.com 
+44(0)20 7336 6100 sara.peerun[.]visiongainglobal.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Visiongain securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Visiongain / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)